about
Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclidesUnderscoring the influence of inorganic chemistry on nuclear imaging with radiometals.Evaluation of (99) (m)TcN-MPO as a new myocardial perfusion imaging agent in normal dogs and in an acute myocardial infarction canine model: comparison with (99) (m)Tc-sestamibi.Minimizing liver uptake of cationic Tc radiotracers with ether and crown ether functional groupsDevelopment of kit formulations for (99m) TcN-MPO: a cationic radiotracer for myocardial perfusion imaging.Effect of co-ligands on chemical and biological properties of (99m)Tc(III) complexes [(99m)Tc(L)(CDO)(CDOH)2BMe] (L=Cl, F, SCN and N3; CDOH2=cyclohexanedione dioxime).Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexesMetallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen.Radiolabeled bombesin derivatives for preclinical oncological imaging.99mTc-centered one-pot synthesis for preparation of 99mTc radiotracers.Radiolabeled oligonucleotides for antisense imaging.Image-guided nanosystems for targeted delivery in cancer therapy.Radiolabeling approaches of nanoparticles with (99m) Tc.A nuclear chocolate box: the periodic table of nuclear medicine.(99m)Tc-bioorthogonal click chemistry reagent for in vivo pretargeted imaging.Radionuclide (131)I-labeled multifunctional dendrimers for targeted SPECT imaging and radiotherapy of tumors.Clinically Approved Nanoparticle Imaging Agents.Optimized preparation of a (99m)Tc-radiolabeled probe for tracing microRNA.Recent achievements in Tc-99m radiopharmaceutical direct production by medical cyclotrons.Synthesis and biodistribution of a new (99m) Tc-oxo complex with deoxyglucose dithiocarbamate for tumor imaging.Synthesis of multidentate ligands with amido or amino donor groups for the preparation of rhenium and technetium radiopharmaceuticals.Comparison of the Absorbed Dose for (99m)Tc-Diethylenetriaminepentaacetic Acid and (99m)Tc-Ethylenedicysteine Radiopharmaceuticals using Medical Internal Radiation Dosimetry.How do HYNIC-conjugated peptides bind technetium? Insights from LC-MS and stability studies.A new [2 + 1] mixed ligand concept based on [99(m)Tc(OH2)3(CO)3]+: a basic study.Formulation of 99mTechnetium-labeled leuprolide loaded liposomes and its biodistribution study in New Zealand white female rabbits for assessment of its uterine targeting efficiency.99m Tc-labeled NGR-chlorambucil conjugate, 99m Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging.Preparation and biological evaluation of (99m)Tc-ropinirole as a novel radiopharmaceutical for brain imaging.Radioiodinated acebutolol as a new highly selective radiotracer for myocardial perfusion imaging.Advances in targeting the folate receptor in the treatment/imaging of cancers.Influence of the Generator in-Growth Time on the Final Radiochemical Purity and Stability of Radiopharmaceuticals
P2860
Q24649091-89F30983-7DD7-4DE0-BF79-E54616CE8EADQ34119201-8A8BD9B5-8A1A-4876-BC98-EC65CA2B17B5Q34316502-7822BF24-0901-4272-B2A2-9D4308A3DCACQ34391531-B51520AE-7337-460A-8E5E-D33532914898Q35230031-37E0C9B6-FC78-4214-80EC-F9750363D627Q35237365-4392673E-F809-4CCA-AEDD-09E9EE774871Q36843952-C2C73658-4A4A-4C66-8CAB-6BBC10EBB94CQ37026964-02FB377C-37CE-43A4-B700-A7E847D01090Q37207310-9D97FC2F-23A8-4F31-BB27-D45EF99C50C8Q37674035-3ED70DD4-FBB2-42C2-9D7A-6660E306774FQ37849601-27E757CE-6479-412D-8791-0168C7E85962Q37913042-91F2F68D-894F-4308-9632-C10E81D3E847Q38011794-7361BE2A-28D7-4C1B-9915-8DDB8B2E7C37Q38101305-CDB878E9-E642-4D42-9196-5E4BB90B7428Q38269216-72315FC8-747C-4C63-B4B0-7F9FBA07AE7AQ38794260-C9E5B8DD-6BB3-4256-BE01-3294E09C733EQ38827018-46CA5659-D7AA-4923-AA10-A789313DEDCFQ38979886-EDEB2F19-EA58-4EAD-B9A6-EECA17200660Q39113192-835EB92E-2A89-4B6E-8A54-1C3717C08044Q39263247-74484DD3-2D96-47B7-96B3-09B1B6636EB6Q39434037-15312B6A-C970-4CC2-8DBB-9DDF632BDC92Q40679530-536ACFC6-D08D-4C19-B467-1293E9510BABQ42425637-2E8CFEC8-074C-4131-B1B9-AA9046BAF5D5Q43063217-5FA3BA3B-CFC8-4CED-A9ED-47D192A5BF57Q44977566-37B79919-C63D-472B-8855-DB6179BFA4E0Q47596256-56E5B98C-7164-44E0-9AC2-4646E9BF3FA9Q48091368-BFEA9C0D-29E0-425B-B7EF-E2EC8244ECBEQ48879813-0D3786A3-E5A5-49B5-BF52-DA74662353DDQ53829960-F1E6F040-5F75-422A-918C-E0EE1290B0A7Q55315165-F9F665D2-0DAD-4629-B614-A681DB0B3D90Q57740776-704F97C8-980A-4651-97F5-3CDEAC9949E4
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@ast
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@en
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@nl
type
label
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@ast
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@en
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@nl
prefLabel
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@ast
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@en
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@nl
P2093
P356
P1476
Evolution of Tc-99m in diagnostic radiopharmaceuticals.
@en
P2093
Banerjee S
Ramamoorthy N
P304
P356
10.1053/SNUC.2001.26205
P577
2001-10-01T00:00:00Z